WSI, Major Shareholder Divests Large Stake! What Should Investors Do? On August 29, 2025, WSI’s largest shareholder sold a significant portion of their stake. This news shocked investors and increased uncertainty about the stock’s future direction. How will this divestment impact the company’s future? This article analyzes WSI’s business status, financial condition, and the implications … Read more
Chong Kun Dang Enters the Hypertension Treatment Market: Should Investors Pay Attention to Telminuvo’s Approval? Chong Kun Dang’s newly developed hypertension treatment, Telminuvo, has received approval from the Ministry of Food and Drug Safety (MFDS). How will this news impact Chong Kun Dang Holdings’ stock price? This article delves into the significance of Telminuvo’s approval, … Read more
Korea BioNics’ Partial Vienox Lawsuit Win: An Investor Analysis Korea BioNics recently achieved a partial victory in the Vienox lawsuit. What implications does this hold for the company’s future? In this article, we delve into the significance of the ruling, analyze Korea BioNics’ fundamentals, and explore potential investment strategies. Read on to find out more. … Read more
Chong Kun Dang’s New Hypertension Drug Telminuvo Approved: Is it an Investment Opportunity? Chong Kun Dang has secured a new growth engine with the domestic approval of Telminuvo (CKD-828). However, potential risks exist, including recent sluggish performance and intensified market competition. This article analyzes the implications of Telminuvo’s approval and key factors investors should consider, … Read more
Avion’s ₩79.4 Billion Rights Offering: Should You Invest? On August 29, 2025, Avion announced a significant rights offering. While securing funds for R&D is generally seen as positive, potential stock dilution warrants careful consideration. This article provides a comprehensive analysis of Avion’s rights offering, its implications for investors, and potential investment strategies. 1. What Happened … Read more
Orum Therapeutics Announces Large Shareholding Report! What’s Next for the Stock? On August 29, 2025, Orum Therapeutics released its large shareholding report, drawing attention from investors. How will the change in major shareholders’ stakes affect the company’s value and future stock price? This article analyzes the key contents of the report and presents an investment … Read more
Phacell Bio’s Q1 Earnings Disappoint… What Should Investors Do? Phacell Bio, a developer of anti-cancer immunotherapies, announced its Q1 2024 earnings. Contrary to market expectations, losses continued, and revenue was zero. However, clinical pipelines are steadily progressing, and the pet business, a new growth engine, is expanding. Is now the right time to invest in … Read more
Korea United Pharm Secures New Growth Engine? Korea United Pharm has obtained approval for Siloduo SR, a combination drug for the treatment of chronic arterial occlusive disease. What does this news mean for investors? This article analyzes the potential impact of Siloduo SR’s launch on Korea United Pharm’s stock price and highlights key factors to … Read more
Can iCure Escape Delisting? iCure (175250)’s delisting review has been extended, increasing investor anxiety. Despite improved financials and growth in the cosmetics business, the possibility of delisting remains. This article analyzes iCure’s current situation, provides future outlook, and guides investors on the actions they should take. What Happened? On August 27, 2025, iCure announced that … Read more
Samchundang Pharm Decides to Dispose of Treasury Stock Worth 29.5 Billion Won! What’s the Investment Strategy? Samchundang Pharm’s announcement of treasury stock disposal is drawing attention from investors. Is this decision good news or bad news? This article closely analyzes the background and impact of the treasury stock disposal and presents key points investors should … Read more